Estimating Quality-Adjusted Life Years and Life-Years Gained in Glioblastoma Patients: Analysis from the TIGER Trial
Author(s)
Jorge F. Nino de Rivera Guzman, MSc1, Bruce Wang, PhD2;
1Novocure, Health Economy specialist, Glendale, CO, USA, 2Novocure, Portsmouth, NH, USA
1Novocure, Health Economy specialist, Glendale, CO, USA, 2Novocure, Portsmouth, NH, USA
Presentation Documents
OBJECTIVES: To quantify the Quality-Adjusted Life Years (QALYs) and life-years gained associated with Tumor Treating Fields (TTFields) in glioblastoma treatment and to assess its impact in a real-world setting.
METHODS: This analysis utilized data from the intention-to-treat (ITT) population of the real-world TIGER study, a prospective, non-interventional, multicenter trial that enrolled 710 patients from 2017 to 2019 across 81 centers in Germany. Kaplan-Meier survival curves for overall survival (OS) and progression-free survival (PFS) were used, supplemented by data from the EF-14 trial for OS. Utility values were sourced from published literature. A three-state partitioned survival model (Stable Disease, Progressive Disease, Death) was employed to estimate life-year and QALY gains. Sensitivity analyses were conducted to assess the robustness of the utility values and model assumptions.
RESULTS: The TIGER study results aligned with findings from the EF-14 trial, demonstrating consistent gains in life years and QALYs. Baseline patient characteristics in the TIGER population were similar to those in EF-14, with a median age of 58 years compared to 56 in EF-14, and 64.1% of patients being men compared to 68% in EF-14. Patients treated with TTFields plus temozolomide (TMZ) in the TIGER study had a life year gain of 3.42, compared to 3.34 in EF-14, reflecting an incremental increase of 0.08 years. Similarly, QALYs improved from 2.57 in EF-14 to 2.67 in TIGER, representing a gain of 0.1 QALYs. Sensitivity analyses confirmed these findings, affirming the robustness and reliability of the results.
CONCLUSIONS: The TIGER trial validates the clinical efficacy of TTFields observed in the EF-14 trial and strengthens the external validity of these findings by incorporating real-world data. The consistency of results between controlled trials and real-world evidence supports the broader application of TTFields in glioblastoma treatment, demonstrating its effectiveness in improving both life-years and QALYs in routine healthcare settings.
METHODS: This analysis utilized data from the intention-to-treat (ITT) population of the real-world TIGER study, a prospective, non-interventional, multicenter trial that enrolled 710 patients from 2017 to 2019 across 81 centers in Germany. Kaplan-Meier survival curves for overall survival (OS) and progression-free survival (PFS) were used, supplemented by data from the EF-14 trial for OS. Utility values were sourced from published literature. A three-state partitioned survival model (Stable Disease, Progressive Disease, Death) was employed to estimate life-year and QALY gains. Sensitivity analyses were conducted to assess the robustness of the utility values and model assumptions.
RESULTS: The TIGER study results aligned with findings from the EF-14 trial, demonstrating consistent gains in life years and QALYs. Baseline patient characteristics in the TIGER population were similar to those in EF-14, with a median age of 58 years compared to 56 in EF-14, and 64.1% of patients being men compared to 68% in EF-14. Patients treated with TTFields plus temozolomide (TMZ) in the TIGER study had a life year gain of 3.42, compared to 3.34 in EF-14, reflecting an incremental increase of 0.08 years. Similarly, QALYs improved from 2.57 in EF-14 to 2.67 in TIGER, representing a gain of 0.1 QALYs. Sensitivity analyses confirmed these findings, affirming the robustness and reliability of the results.
CONCLUSIONS: The TIGER trial validates the clinical efficacy of TTFields observed in the EF-14 trial and strengthens the external validity of these findings by incorporating real-world data. The consistency of results between controlled trials and real-world evidence supports the broader application of TTFields in glioblastoma treatment, demonstrating its effectiveness in improving both life-years and QALYs in routine healthcare settings.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE153
Topic
Economic Evaluation
Disease
SDC: Oncology